- What's New?
VeraLight announces CE mark approval.
Pear Healthcare introduces SCOUT DS in Canada.
Watch the SCOUT DS demonstration video.
- Sign Up
Join our e-mail list to get the latest updates on SCOUT DS® technology
- Subscribe to our RSS Feed
Welcome to VeraLight
VeraLight is a privately-held medical device company that was established in 2004 to develop the SCOUT DS® noninvasive screening device for prediabetes and type 2 diabetes. The SCOUT DS is the first noninvasive optical skin test that can replace conventional blood-based diabetes screening. The easy to operate SCOUT DS needs no blood and does not require fasting. The patient simply places a forearm on the portable table-top unit, and a quantitative result is reported in under four minutes.
SCOUT DS is Indicated for Use for the noninvasive screening of individuals 18 years or older who are at risk for prediabetes and/or type 2 diabetes to determine whether diagnostic testing is necessary. Prediabetes is defined as impaired glucose tolerance.
SCOUT DS has received approval from Health Canada for commercial distribution and it has been granted a CE Mark in the European Union.
US Caution: Federal law restricts the SCOUT DS system to investigational use only. Commercial distribution has not been granted by the US FDA. See SCOUT DS Operation Manual for descriptions of all relevant Warnings, Cautions, Contraindications, & Safety Information.